Menu
 

Search abstracts


Evaluation of the safety and efficacy of m-beam and m-beac due to the shortage supply of melphalan

  • At: 2018 FIP Congress in Glasgow (Scotland)
  • Type: Poster
  • By: MIYAGAWA, Keiko (Kameda Medical Center)
  • Co-author(s): Keiko Miyagawa: Pharmacy, Kameda Medical Center, Kamogawa, Japan
    Yusuke Nakagawa: Pharmacy, Kameda Medical Center, Kamogawa, Japan
    Tatsuya Isezaki: Pharmacy, Kameda Medical Center, Kamogawa, Japan
    Koji Masuda
    Osamu Yasumuro: Pharmacy, Kameda Medical Center, Kamogawa, Japan
    Ryohkan Funakoshi: Pharmacy, Kameda Medical Center, Kamogawa, Japan
    Kosei Matsue: Hematology, Kameda Medical Center, Kamogawa, Japan
  • Abstract:

    Background

    Melphalan IV (Mel) distribution has been suspended globally due to manufacturing process difficulties occurring in November 2015. We have been using the combination of Ranimustine/Etoposide/Cytarabine/Cyclophosphamide (M-BEAC) as pretreatment for autologous stem-cell transplantation (ASCT) instead of..

  • The access to the whole abstract and the presentation file is available to FIP members and to congress participants of that specific congress. Please login
Last update 13 May 2019

FIP Congresses